PSCA: prostate stem cell antigen and uses thereof

US7407656B2 · kind B2 · utility

Assignees

• The Regents of the University of California · US
• Latency, LLC · US

Inventors

• Robert E. Reiter · Los Angeles, US
• Owen N. Witte · West Hollywood, US
• Douglas Saffran · Los Angeles, US
• Aya Jakobovits · Beverly Hills, US

Key dates

• Filing date: Jan 29, 2004
• Grant date: Aug 5, 2008
• Expiry date: Mar 4, 2025

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/705
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.